CDMOs offering Vaccine Manufacturing with mRNA
11 published
11 published CDMOs match Vaccine Manufacturing and mRNA.
Locations in this set include United States, China, Spain, United Kingdom, Canada, and India.
Capabilities that show up most often in this set: CMC Analytical Development, mRNA Manufacturing, Process Development, Quality Control Testing, and Recombinant Protein Manufacturing.
Matching companies
Artis BioSolutionsIntegrated CDMO platform combining proprietary enzymatic synthetic DNA production with advanced therapy development and GMP manufacturing for mRNA, gene editing, viral vectors, cell therapies, and vaccines.
Creative BiogeneCreative Biogene provides viral vector manufacturing, cell line development, and RNA therapeutic platforms including AAV, lentivirus, adenovirus production, circular RNA synthesis, and lipid nanoparticle formulation for gene therapy and vaccine applications.
ElevateBioAdvanced therapies CDMO providing discovery, process development, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA, and gene editing programs from preclinical through commercial scale.
Maravai LifeSciencesLeading provider of nucleic acid products, custom enzymes, and bioprocess analytics supporting vaccine, therapeutic, and diagnostic development from discovery through commercialization, with mRNA CDMO services including proprietary CleanCap® capping technology.
National ResilienceEnd-to-end CDMO specializing in complex modalities including cell, gene, and RNA-based therapies with North American manufacturing facilities and development capabilities.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
ROISSterile fill-finish CDMO for biologics, vaccines and ADCs, offering prefilled syringes, cartridges and vials across five US and European sites. It also supports oral solid dose manufacturing and drug substance development.
Samsung BiologicsLeading CDMO offering end-to-end biologics development and manufacturing from cell line development through aseptic fill-finish, with capabilities in drug substance, drug product, ADC, and mRNA services.
Symbiosis Pharmaceutical ServicesUK-based fill-finish CDMO offering rapid access to GMP aseptic manufacturing for clinical and commercial injectable drug products across mAbs, ATMPs, ADCs, RNA, peptides, vaccines, and small molecules.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
WuXi VaccinesGlobal CDMO specializing in end-to-end vaccine and prophylactic antibody development and manufacturing across mammalian, viral, and microbial platforms with GMP-certified facilities and over 550 million doses delivered.
Markdown mirror: /explore/vaccine-manufacturing/mrna.md